Research fellow

Oliver Scholle

Curriculum vitae

  • since October 2014 Research Fellow at Leibniz Institute for Prevention Research and Epidemiology - BIPS in the department Clinical Epidemiology, Unit Epidemiology of Neuropsychiatric Disorders (since Dec 2015 - until then in Unit Drug Utilization and Health Services Research)
  • March 2012 - October 2014 Master of Science in Consumer Health Care (Charité, Berlin).
    Master thesis at BIPS in the department Clinical Epidemiology, Unit Drug Safety: "Comedication with antipsychotics and antidepressants of ADHD children and adolescents: a population-based cohort study"
  • July 2012 - September 2014 Nationwide locum pharmacist
  • April 2010 - April 2012 Employee in a pharmacy
  • October 2010 - March 2019 Employment in and initiation of the internet platform pharma4u
  • December 2008 - June 2009 Diploma thesis at the Institute of Clinical and Experimental Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel: "Development of a LC/MS method for analysing Piritramide in plasma"
  • October 2003 - November 2008 Study of Pharmacy at the Universities of Marburg and Kiel

Research interests

  • Health Services Research
  • Drug Utilization Research
  • Pharmacoepidemiology
  • Neuropsychiatric diseases (particularly ADHD)
  • Drug Information
  • Pharmaceutical law

Memberships

Projects

Selected publications

  • Articles with peer-review

  • Scholle O, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for receiving medication and/or psychotherapy in children newly diagnosed with ADHD: A longitudinal population-based cohort study. Journal of Attention Disorders. 2020;24(2):255-264.
    https://doi.org/10.1177/1087054718816172
  • Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
    https://doi.org/10.1111/joim.12990
  • Vassilev ZP, Soriano-Gabarró M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtälä J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: Results from observational studies in three countries. Future Oncology. 2020;16(25):1889-1901.
    https://doi.org/10.2217/fon-2020-0315
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
    https://doi.org/10.1097/JCP.0000000000000980
  • Scholle O, Jilani H, Riedel O, Banaschewski T, Hadjigeorgiou C, Hunsberger M, Iguacel I, Molnár D, Pala V, Russo P, Veidebaum T, Zaqout M, Pohlabeln H, on behalf of the I.Family consortium. Use of nutritional supplements in youth with medicated and unmedicated attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2019;29(1):58-65.
    https://doi.org/10.1089/cap.2018.0060
  • Castellsagué J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthan S. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2018;27(9):953-961.
    https://doi.org/10.1002/pds.4584
  • Scholle O, Banaschewski T, Enders D, Garbe E, Riedel O. Use and characteristics of antipsychotic/methylphenidate combination therapy in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2018;28(6):415-422.
    https://doi.org/10.1089/cap.2018.0024
  • Castellsagué J, Perez-Gutthan S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Kieler H, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety. 2017;26(6):615-624.
    https://doi.org/10.1002/pds.4167
  • Books

  • Scholle O. Beratungsscheibe Selbstmedikation. Eschborn: Govi-Verlag Pharmazeutischer Verlag GmbH; 2015.
  • Presentations at scientific meetings/conferences (invited)

  • Scholle O. German Pharmacoepidemiological Research Database (GePaRD): Möglichkeiten und Grenzen. 35. Jahreskongress der Deutschen Gesellschaft für Pharmazeutische Medizin, 28.-29. März 2019, Berlin.
  • Presentations at scientific meetings/conferences

  • Scholle O, Grill S, Haug U. Early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. 15. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 29. September 2020, Online-Vortrag.
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. 15. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 29. September 2020, Online-Vortrag.
  • Scholle O, Kollhorst B, Haug U. Diclofenac use and cardiovascular contraindications: Risk minimisation measures lacking effectiveness in Germany - A claims data analysis. 14. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 11.-13. September 2019, Ulm.
  • Schröder C, Scholle O, Riedel O. Using administrative data to examine extent and risks of psychotropic drug use in children and adolescents. Possibilities and limitations. Congress "Health - Exploring Complexity: An Interdisciplinary Systems Approach (HEC2016)." Joint Annual Meeting of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS), the German Society for Epidemiology (DGEpi), the International Epidemiological Association - European Region (IEA-EEF) and the European Federation for Medical Informatics Association (EFMI), 28 August-2 September 2016, Munich. (Abstract published in: European Journal of Epidemiology. 2016;31(Suppl.1):S179)
  • Posters at scientific meetings/conferences

  • Scholle O, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster.
  • Scholle O, Grill S, Haug U. Changes in early life exposure to antibiotics: A comparison of birth cohorts based on German claims data. Kinder- und Jugendmedizin aktuell, 17.-19. September 2020, Online-Poster.
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster.
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Prevalence of chronic drug use in pediatrics: Comprehensive overview based on German claims data. Kinder- und Jugendmedizin aktuell, 17.-19. September 2020, Online-Poster.
  • Scholle O, Kollhorst B, Haug U. Are the risk minimization measures for diclofenac effective? A pre-post comparison based on German claims data. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):954)
  • Kölch M, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Scholle O. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. 65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), 22-27 October 2018, Seattle, USA.
  • Scholle O, Banaschewski T, Jilani H, Riedel O, Pohlabeln H. Gebrauch von Nahrungsergänzungsmitteln bei Kindern mit medikamentös und nicht medikamentös behandelter ADHS. 13. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2018, Bremen.
  • Scholle O, Fegert JM, Kollhorst B, Öztürk E, Riedel O, Kölch M. Predictors for pharmacological and psychotherapeutic treatment in children newly diagnosed with ADHD. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 22-26 August 2018, Prague, Czech Republic.
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Arana A, Bui C, Laguna C, Prados-Torres A, Roso-Llorach A, Perez-Gutthan S. Impact of risk-minimization measures on the use of cilostazol in Europe. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 26-30 August 2017, Montreal, Canada. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2017;26(Suppl.2):S428)
  • Castellsagué J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A, Bui C, Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthan S. Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2016, Dublin, Ireland.

For further publications please follow this link:

Prizes and awards

  • Spotlight Poster Winner 2020 in the category of "Pediatrics"
    International Society for Pharmacoepidemiology (2020)
    Poster mit dem Titel "Changes in Early Life Exposure to Antibiotics: A Comparison of Birth Cohorts Based on German Claims Data"
  • ICPE Scholarship 2019
    International Society for Pharmacoepidemiology (2019)
    Attending the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Philadelphia, PA, USA

Teaching

  • since May 2014 Lecturer for the subjects Pharmacy, Pharmaceutical Law & Pharmakology in the Pharmaakademie GmbH & Co. KG

The responsibility for the content of this page lies with Oliver Scholle.